Skip to main content

Volume 13 Supplement 1

The evolution of anti-TNF therapy in rheumatic disease: experience, insights and advances

Reviews

Edited by Joachim Kalden

Publication of this supplement is sponsored by Merck & Company, Inc, Whitehouse Station, New Jersey, USA.

  2. Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Contro...

    Authors: Josef S Smolen and Paul Emery
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S2
    Content type: Review Published on:

  3. Treatment strategies for rheumatoid arthritis (RA) will continue to evolve as new drugs are developed, as new data become available, and as our potential to achieve greater and more consistent outcomes becomes...

    Authors: Ferdinand C Breedveld and Bernard Combe
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S3
    Content type: Review Published on:

  4. Structural changes of bone and cartilage are a hallmark of inflammatory joint diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Despite certain similaritie...

    Authors: Georg Schett, Laura C Coates, Zoe R Ash, Stefanie Finzel and Phillip G Conaghan
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S4
    Content type: Review Published on:

  5. Treatment of inflammatory arthritides - including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis - has seen much progress in recent years, partially due to increased understanding of the...

    Authors: Paul P Tak and Joachim R Kalden
    Citation: Arthritis Research & Therapy 2011 13(Suppl 1):S5
    Content type: Review Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2023
    Submission to first editorial decision (median days): 9
    Submission to acceptance (median days): 111

    Usage 2023
    Downloads: 3,331,819
    Altmetric mentions: 1,885

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us